United States set
language
Menu Shopping cart $0 Search
Distributed product

SDMA human ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:Symmetric Dimethylarginine
  • Species:Human
This product is not available in United States!
Cat. No. Size Price


EA214/96 96 wells (1 kit)
PubMed Product Details
Technical Data

Cat # changed from REA203/96 to EA214/96

Type

Competitive ELISA, Immobilized antigen

Description

The competitive SDMA human ELISA uses the microtiter plate format. SDMA is bound to the solid phase of the microtiter plate. SDMA in the samples is acylated and competes with solid phase bound SDMA for a fixed number of rabbit anti-SDMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-antiserum complexes are removed by washing. The antibody bound to the solid phase SDMA is detected by anti-rabbit / peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase SDMA is inversely proportional to the SDMA concentration of the sample.

Applications

Serum, Plasma-EDTA

Sample Requirements

20 μl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0–3.0 µmol/l

Limit of Detection

0.03 μmol/l

Spiking Recovery

97%(EDTA-plasma), 93% (serum)

Dilution Linearity

97% (EDTA-plasma)

Note

The kits are CE-IVD certified and intended for professional use.

Summary

Features

  • For in vitro diagnostic use only
  • standards 1-6: 0-3.0 µmol/l (0-606 ng/ml)
  • limit of detection 0.03 μmol/l
  • Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materials should be handled as potentially infectious.

Research topic

Renal disease

Summary

Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function an essential component of diagnostics in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. As the most commonly used marker of renal excretory function, serum creatinine concentration, does not adequately respond to mild to moderate impairment of renal function, more sensitive markers for renal excretory function are urgently seeked, especially in mild stages of renal impairment. SDMA is a methylated derivative of the amino acid L-arginine (symmetric dimethylarginine). SDMA is eliminated from the body exclusively by renal excretion; therefore SDMA plasma concentration is tightly related to renal function. Thus, quantification of plasma SDMA is an adequate means to assess renal function, as could be demonstrated in a series of recent clinical trials: In 18 clinical studies involving more than 2,100 patients systemic SDMA concentrations were highly correlated with inulin clearance as well as with various clearance estimates and better corresponded to mild renal function impairment than serum creatinine. Thus, SDMA exhibits properties of a reliable marker of renal function. Furthermore, there is evidence showing that elevated SDMA levels, as they may occur in renal function impairment, may prospectively indicate future risk of cardiovascular disease and mortality independently of the level of renal impairment.

Product References (3)

References

  • Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006 Apr;17 (4):1128-34
  • Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant. 2006 Sep;21 (9):2446-51
  • Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis. 2006 Apr;185 (2):271-7
Related Products Docs